NCT02441517View on ClinicalTrials.gov

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 28, 2015

Primary Completion Date

March 15, 2017

Study Completion Date

March 15, 2017

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

Enzalutamide

Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.

Trial Locations (5)

10029

Site US10004, New York

29425

Site US10001, Charleston

29572

Site US10002, Myrtle Beach

60201

Site US10003, Evanston

01605

Site US10006, Worcester

Sponsors

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY